B r i e f c o m m u n i c at i o n s
Presenilin 1 (PS1) is closely linked to Alzheimer's disease, as it is an integral component of γ-secretase, an enzyme that is required for the production of amyloid beta 1 , and also as it is the most commonly mutated protein in familial Alzheimer's disease 2 . The mechanism by which mutations in PS1 lead to Alzheimer's disease remains an open question, but a common feature of cells lacking PS1 or expressing familial Alzheimer's disease-linked PS1 mutants is defective calcium signaling 3, 4 . Homeostatic synaptic scaling, a compensatory form of synaptic plasticity that maintains action potential firing rates in an optimal range in both young and adult neurons 5, 6 , is triggered by changes in intracellular calcium levels 7 . To determine whether PS1 is required for homeostatic synaptic scaling, we treated dissociated cultures of mouse hippocampal neurons derived from Psen1 −/− embryos and plated onto a feeder layer of wild-type astrocytes with tetrodotoxin (TTX, 1 µM) for 24-48 h (see Supplementary Methods). Psen1 −/− neurons failed to scale up synaptic strengths in response to blockade of action potential firing, whereas wild-type neurons showed a robust increase in spontaneous miniature excitatory postsynaptic current (mEPSC) amplitude (wild type, 18.1 ± 1.4 pA, n = 11; wild type + TTX, 34.3 ± 4.0 pA, n = 15; Psen1 −/− , 18.4 ± 1.1 pA, n = 25; Psen1 −/− + TTX, 19.1 ± 1.4 pA, n = 35; ANOVA, P < 0.0001; Fig. 1a,b) . The similarity between mEPSC amplitudes in untreated Psen1 −/− and wild-type neurons suggests that the inability of Psen1 −/− neurons to scale up was not a result of occlusion (that is, mEPSC amplitudes were not maximally scaled up before network silencing) or a general defect in the mechanisms establishing basal synaptic strength. Treatment of Psen1 −/− neurons with the GABA A receptor antagonist bicuculline (20 µM) for 48 h to enhance network activity produced a significant decrease in mEPSC amplitude (Psen1 −/− , 16.0 ± 0.8 pA, n = 22; Psen1 −/− + bicuculline, 12.8 ± 0.9 pA, n = 25; t test, P < 0.02). Acute (≤30 h) virally mediated expression of wild-type PS1 rescued scaling up in Psen1 −/− neurons treated with TTX (Psen1 −/− + green fluorescent protein (GFP), 19.3 ± 2.5 pA, n = 5; Psen1 −/− + GFP + TTX, 21.0 ± 1.2 pA, n = 17; Psen1 −/− + PS1, 20.2 ± 1.5 pA, n = 13; Psen1 −/− + PS1 + TTX, 31. 9 ± 2.4 pA, n = 21; ANOVA, P < 0.01; Fig. 1c) , demonstrating that the inability of Psen1 −/− neurons to scale up was not a result of an irreversible developmental defect. Together, these data indicate that PS1 is required for the scaling up of excitatory synaptic strengths in response to a suppression of network activity, but is not needed for scaling down in response to enhancement of network activity or for setting basal mEPSC amplitudes.
Scaling up of synaptic strengths in response to TTX treatment is triggered by a drop in somatic calcium levels and a consequent reduction of CaMKIV activation 7 . Because PS1 is known to be involved in regulating calcium release from internal stores 3,4 , we wondered whether the failure of Psen1 −/− neurons to scale up could be a result of aberrantly high levels of somatic calcium that might maintain CaMKIV activation in the absence of action potential firing. To test this possibility, we pharmacologically inhibited CaMKIV activity by treating Psen1 −/− neurons with Sto-609 (2 µM) and dantrolene (10 µM) for 3-4 h. Sto-609 is a CaMKK inhibitor that has been shown to modulate homeostatic synaptic plasticity through downstream inhibition of CaMKIV 7, 8 . Dantrolene is a ryanodine receptor antagonist that suppresses the release of calcium from internal stores. This treatment more than doubled the amplitude of mEPSCs in wild-type neurons, but, in spite of bypassing the requirement for a drop in somatic calcium to inactivate CaMKIV, Psen1 −/− neurons still failed to scale up mEPSC amplitudes (wild type, 13.9 ± 1.2 pA, n = 7; wild type + Sto-609 and dantrolene, 30.3 ± 4.0 pA, n = 9; Psen1 −/− , 14.7 ± 1.3 pA, n = 6; Psen1 −/− + Sto-609 and dantrolene, 16.8 ± 1.2 pA, n = 13; ANOVA, P < 0.0001; Fig. 1d ). These results suggest that an inability to inactivate CaMKIV is not the primary deficit responsible for the failure of Psen1 −/− neurons to scale.
Having established a role for PS1 in synaptic scaling, we decided to more directly test the potential relevance of a homeostatic synaptic scaling deficit in the development of Alzheimer's disease pathology by investigating the effects of TTX on mEPSC amplitudes in cultured hippocampal neurons derived from mice in which a familial Alzheimer's disease-linked Psen1 mutation, Psen1 M146V , is knocked-in 9 . In Psen1 M146V mice, transcription of the mutant Psen1 is controlled by the endogenous promoter, and protein is expressed at normal physiological levels 9 . Although Psen1 M146V neurons responded more heterogeneously to network silencing than did Psen1 −/− neurons, Psen1 M146V Neurons adapt to long-lasting changes in network activity, both in vivo and in vitro, by adjusting their synaptic strengths to stabilize firing rates. We found that homeostatic scaling of excitatory synapses was impaired in hippocampal neurons derived from mice lacking presenilin 1 (Psen1 −/− mice) or expressing a familial Alzheimer's disease-linked Psen1 mutation (Psen1 M146V ). These findings suggest that deficits in synaptic homeostasis may contribute to brain dysfunction in Alzheimer's disease.
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neurons also failed to show a significant enhancement of mEPSC amplitude with TTX treatment (wild type, 18.7 ± 2.2 pA, n = 15; wild type + TTX, 30.9 ± 3.6 pA, n = 13; Psen1 M146V , 19.0 ± 1.9 pA, n = 21; Psen1 M146V + TTX, 24.8 ± 2.9 pA, n = 26; ANOVA, P < 0.02; Fig. 2a) . To determine whether aberrant γ-secretase activity might be involved, we treated wild-type neurons with the γ-secretase inhibitor L685,458 (5 µM) and TTX for 48 h and found no significant effect on scaling of mEPSC amplitudes in neurons treated with L685,458 (wild type + L685,458, 14.8 ± 1.2 pA, n = 12; wild type + L685,458 + TTX, 25.2 ± 3.1 pA, n = 16; t test, P < 0.01; Fig. 2b ). These findings suggest that the failure of Psen1 −/− and Psen1 M146V neurons to scale normally is a result of a PS1 function that is independent of γ-secretase activity.
Among other deficits, Psen1 −/− neurons have substantially impaired phosphatidylinositol 3-kinase (PI3K)/Akt signaling that is not rescued by virally mediated expression of PS1M146V or mimicked by treatment of wild-type neurons with γ-secretase inhibitor 10, 11 . It has been suggested that PS1 influences PI3K/Akt activity through the promotion of Akt-activating cadherin/PI3K complexes 11 , as well as by effects on the trafficking of cell surface signaling receptors coupled to PI3K/Akt 12 . A role for PI3K/Akt signaling in synaptic scaling is strongly suggested by the findings that inhibition of PI3K blocks homeostatic AMPA receptor delivery to synapses 13 and that PI3K/Akt-mediated phosphorylation of AMPA receptors enhances their delivery to synapses 14 . To determine whether reduced PI3K/Akt signaling in Psen1 M146V neurons contributes to scaling deficits, we expressed a constitutively active Akt (CA-Akt) while treating with TTX and found that synaptic scaling was rescued (GFP, 18.7 ± 2.2 pA, n = 19; GFP + TTX, 19.2 ± 1.9 pA, n = 21; CA-Akt, 20.1 ± 1.2 pA, n = 19; CA-Akt + TTX, 29.5 ± 2.4 pA, n = 21; ANOVA, P < 0.0005; Fig. 2c ). Note that expression of CA-Akt sans TTX treatment did not result in enhanced mEPSC amplitudes, suggesting that Akt activation is necessary, but not sufficient, to induce scaling. Together, our results raise the possibility that impairments in PI3K/Akt-dependent synaptic homeostasis might contribute to the development of cognitive deficits in familial, and perhaps sporadic 15 , Alzheimer's disease. TTX treatment failed to induce a significant increase in mEPSC amplitudes in Psen1 M146V neurons, but did significantly increase mEPSC amplitudes in wild-type neurons (ANOVA, P < 0.02; *Bonferroni's multiple comparison test, P < 0.05). (b) The γ-secretase inhibitor L685,458 (L685) did not affect scaling up of mEPSC amplitudes in TTX-treated wild-type neurons (**unpaired t test, P < 0.01). (c) Virally mediated expression of CA-Akt in Psen1 M146V neurons had no effect on mEPSC amplitudes in the absence of TTX treatment, but restored the ability to scale up in response to TTX treatment (ANOVA, P < 0.0005; ***Bonferroni's multiple comparison test, P < 0.01). Dashed line indicates the average mEPSC amplitude of TTX-treated wild-type neurons (from Fig. 1b) . Error bars represent s.e.m. 
